Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer

被引:6
|
作者
Ferreira, M. R. [1 ,2 ,4 ,5 ]
Thomas, K. [2 ]
Truelove, L. [1 ,2 ]
Khan, A. [1 ,2 ]
Parker, C. [1 ,2 ]
Dearnaley, D. P. [1 ,2 ]
Gulliford, S. [1 ,3 ]
机构
[1] Inst Canc Res, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Univ Coll London Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Kings Coll London, London, England
关键词
Dose-volume constraints; dosimetry; IMRT; pelvic lymph nodes; prostate cancer; gastrointestinal side-effects; SMALL-BOWEL TOXICITY; RADIATION-THERAPY; RECTAL TOXICITY; NORMAL TISSUE; VOLUME; 3D-CRT; PREDICTORS; IMRT;
D O I
10.1016/j.clon.2019.02.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations between intensity-modulated radiotherapy (IMRT) dose-volume data and long-term gastrointestinal toxicity. Materials and methods: Data from a single-centre dose-escalation trial of PLN-IMRT were analysed, including conventionally fractionated (CFRT) and hypofractionated (HFRT) radiotherapy schedules. Associations between volumes of rectum and bowel receiving specified doses and clinician- and patient-reported toxicity outcomes were investigated independently. A metric, delta median (delta M), was defined as the difference in the medians of a volume between groups with and without toxicity at a specified dose and was used to test for statistically significant differences. Results: Constraints were respected in most patients and, when exceeded, led to higher rates of gastrointestinal toxicity. Biologically relevant associations between rectum dose-points and toxicity were more numerous with both mild and moderate toxicity thresholds, but statistical significance was limited after correction for false discovery rate. Rectal V50Gy (CFRT) associated with grade 2+ bleeding; bowel V43Gy and V47 (HFRT/4 days/week schedule) associated with patient-reported loose stools and diarrhoea, respectively. Further investigation showed that CFRT patients with rectal bleeding had a mean rectal V50Gy above the treatment planning constraint. Conclusions: When dose-volume parameters are kept below tight constraints, toxicity is low. Residual dosimetry loses much of its predictive power for gastrointestinal toxicity in the setting of PLN-IMRT for prostate cancer. We have benchmarked dose-volume constraints for safely delivering PLN-IMRT using CFRT or HFRT. (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd.
引用
收藏
页码:374 / 384
页数:11
相关论文
共 50 条
  • [41] Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
    Fink, C. A.
    Ristau, J.
    Buchele, C.
    Klueter, S.
    Liermann, J.
    Hoegen-Sassmannshausen, P.
    Sandrini, E.
    Lentz-Hommertgen, A.
    Baumann, L.
    Andratschke, N.
    Baumgartl, M.
    Li, M.
    Reiner, M.
    Corradini, S.
    Hoerner-Rieber, J. Ho
    Bonekamp, D.
    Schlemmer, H. -P.
    Belka, C.
    Guckenberger, M.
    Debus, J.
    Koerber, S. A.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 46
  • [42] Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial
    Gregucci, Fabiana
    Carbonara, Roberta
    Surgo, Alessia
    Ciliberti, Maria Paola
    Curci, Domenico
    Ciocia, Annarita
    Brana, Luciana
    Ludovico, Giuseppe Mario
    Scarcia, Marcello
    Portoghese, Filippo
    Caliandro, Morena
    Ludovico, Elena
    Paulicelli, Eleonora
    Di Guglielmo, Fiorella Cristina
    Bonaparte, Ilaria
    Fiorentino, Alba
    RADIOLOGIA MEDICA, 2023, 128 (04): : 501 - 508
  • [43] Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial
    Achard, Verane
    Jaccard, Maud
    Vanhoutte, Frederik
    Siva, Shankar
    Heikkila, Reino
    Dirix, Piet
    Liefhooghe, Nick
    Otte, Francois-Xavier
    Gomez-Iturriaga, Alfonso
    Berghen, Charlien
    Shelan, Mohamed
    Conde-Moreno, Antonio
    Campos, Fernando Lopez
    Papachristofilou, Alexandros
    Guckenberger, Matthias
    Meersschout, Sabine
    Putora, Paul Martin
    Zwahlen, Daniel
    Counago, Felipe
    Scorsetti, Marta
    Eito, Clara
    Barrado, Marta
    Zapatero, Almudena
    Muto, Paolo
    Van De Voorde, Lien
    Lamanna, Giorgio
    Koutsouvelis, Nikolaos
    Dipasquale, Giovanna
    Ost, Piet
    Zilli, Thomas
    RADIOTHERAPY AND ONCOLOGY, 2022, 172 : 1 - 9
  • [44] Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer
    Boyer, Matthew J.
    Papagikos, Michael A.
    Kiteley, Rex
    Vujaskovic, Zeljko
    Wu, Jackie
    Lee, W. Robert
    RADIATION ONCOLOGY, 2017, 12
  • [45] Ultrahypofractionated CyberKnife™ based stereotactic radiotherapy versus conventional radiotherapy in patients with prostate cancer - acute toxicity evaluation in two phase II prospective studies
    Glowacki, G.
    Majewski, W.
    Wojcieszek, P.
    Grabinska, K.
    Wozniak, G.
    Miszczyk, L.
    NEOPLASMA, 2017, 64 (04) : 599 - 604
  • [46] PEARLS-A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation
    Murray, Julia
    Cruickshank, Clare
    Bird, Thomas
    Bell, Philip
    Braun, John
    Chuter, Dave
    Ferreira, Miguel Reis
    Griffin, Clare
    Hassan, Shama
    Hujairi, Nabil
    Melcher, Alan
    Miles, Elizabeth
    Naismith, Olivia
    Panades, Miguel
    Philipps, Lara
    Reid, Alison
    Rekowski, Jan
    Sankey, Pete
    Staffurth, John
    Syndikus, Isabel
    Tree, Alison
    Wilkins, Anna
    Hall, Emma
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 37 : 130 - 136
  • [47] The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
    Pollack, Alan
    Karrison, Theodore G.
    Balogh, Alexander G.
    Gomella, Leonard G.
    Low, Daniel A.
    Bruner, Deborah W.
    Wefel, Jeffrey S.
    Martin, Andre-Guy
    Michalski, Jeff M.
    Angyalfi, Steve J.
    Lukka, Himanshu
    Faria, Sergio L.
    Rodrigues, George B.
    Beauchemin, Marie-Claude
    Lee, R. Jeffrey
    Seaward, Samantha A.
    Allen, Aaron M.
    Monitto, Drew C.
    Seiferheld, Wendy
    Sartor, Oliver
    Feng, Felix
    Sandler, Howard M.
    LANCET, 2022, 399 (10338) : 1886 - 1901
  • [48] The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study
    Tan, M. P.
    Harris, V
    Warren-Oseni, K.
    McDonald, F.
    McNair, H.
    Taylor, H.
    Hansen, V
    Sharabiani, M.
    Thomas, K.
    Jones, K.
    Dearnaley, D.
    Hafeez, S.
    Huddart, R. A.
    CLINICAL ONCOLOGY, 2020, 32 (02) : 93 - 100
  • [49] Semiautomated pelvic lymph node treatment response evaluation for patients with advanced prostate cancer: based on MET-RADS-P guidelines
    Liu, Xiang
    Zhu, Zemin
    Wang, Kexin
    Zhang, Yaofeng
    Li, Jialun
    Wang, Xiangpeng
    Zhang, Xiaodong
    Wang, Xiaoying
    CANCER IMAGING, 2023, 23 (01)
  • [50] Extended field or pelvic intensity-modulated radiotherapy with concurrent cisplatin chemotherapy for the treatment of post-surgery multiple pelvic lymph node metastases in cervical cancer patients: a randomized, multi-center phase II clinical trial
    Luo, Weiming
    Li, Yunhai
    Ke, Guihao
    Wu, Xiaohua
    Huang, Xiao
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (01) : 361 - 371